CL2007002853A1 - Procedimiento para predecir la eficacia de la inmunoterapia para cancer en un individuo, con respecto al beneficio clinico, que comprende proveer una muestra de sangre de dicho individuo, determinar el numero de linfocitos y neutrofilos en la sangre, - Google Patents

Procedimiento para predecir la eficacia de la inmunoterapia para cancer en un individuo, con respecto al beneficio clinico, que comprende proveer una muestra de sangre de dicho individuo, determinar el numero de linfocitos y neutrofilos en la sangre,

Info

Publication number
CL2007002853A1
CL2007002853A1 CL200702853A CL2007002853A CL2007002853A1 CL 2007002853 A1 CL2007002853 A1 CL 2007002853A1 CL 200702853 A CL200702853 A CL 200702853A CL 2007002853 A CL2007002853 A CL 2007002853A CL 2007002853 A1 CL2007002853 A1 CL 2007002853A1
Authority
CL
Chile
Prior art keywords
individual
neutrrogiles
preach
immunotherapy
lymphocytes
Prior art date
Application number
CL200702853A
Other languages
English (en)
Inventor
Loibner Hans
Original Assignee
Loibner Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loibner Hans filed Critical Loibner Hans
Publication of CL2007002853A1 publication Critical patent/CL2007002853A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
CL200702853A 2006-10-03 2007-10-03 Procedimiento para predecir la eficacia de la inmunoterapia para cancer en un individuo, con respecto al beneficio clinico, que comprende proveer una muestra de sangre de dicho individuo, determinar el numero de linfocitos y neutrofilos en la sangre, CL2007002853A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0165106A AT504231A1 (de) 2006-10-03 2006-10-03 Prädiktive parameter

Publications (1)

Publication Number Publication Date
CL2007002853A1 true CL2007002853A1 (es) 2008-05-23

Family

ID=38738831

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702853A CL2007002853A1 (es) 2006-10-03 2007-10-03 Procedimiento para predecir la eficacia de la inmunoterapia para cancer en un individuo, con respecto al beneficio clinico, que comprende proveer una muestra de sangre de dicho individuo, determinar el numero de linfocitos y neutrofilos en la sangre,

Country Status (11)

Country Link
US (1) US8062625B2 (es)
EP (2) EP2453235A1 (es)
AR (1) AR060202A1 (es)
AT (1) AT504231A1 (es)
AU (1) AU2007304868B2 (es)
CA (1) CA2669994A1 (es)
CL (1) CL2007002853A1 (es)
DK (1) DK2089708T3 (es)
PE (1) PE20080975A1 (es)
TW (1) TW200826902A (es)
WO (1) WO2008040044A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105787A (zh) * 2008-05-29 2011-06-22 百时美施贵宝公司 用于预测患者对共刺激通道调节的应答的方法
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2820423A4 (en) * 2012-03-02 2016-05-11 H Lee Moffitt Cancer Ct & Res MATERIALS AND METHOD FOR DIFFERENTIATED TREATMENT OF CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT528767E (pt) 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
WO1993024647A1 (en) 1992-05-22 1993-12-09 Sandoz Ltd. Anti-idiotypic monoclonal antibodies against the lewis y-specific monoclonal antibody br55-2 and their uses
US6820235B1 (en) 1998-06-05 2004-11-16 Phase Forward Inc. Clinical trial data management system and method
SI1230932T1 (en) 1999-01-13 2005-06-30 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Use of antibodies for anticancer vaccination
AU2002225959A1 (en) 2000-11-09 2002-05-21 Mayo Foundation For Medical Education And Research Absolute lymphocyte recovery and cancer survival
US6879970B2 (en) 2001-04-02 2005-04-12 Invivodata, Inc. Apparatus and method for prediction and management of subject compliance in clinical research
US6904434B1 (en) 2001-12-18 2005-06-07 Siebel Systems, Inc. Method and system for providing real-time clinical trial enrollment data
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper

Also Published As

Publication number Publication date
PE20080975A1 (es) 2008-07-19
EP2453235A1 (en) 2012-05-16
DK2089708T3 (da) 2012-12-03
EP2089708B1 (en) 2012-08-15
AR060202A1 (es) 2008-06-04
EP2089708B9 (en) 2013-04-10
AU2007304868B2 (en) 2013-06-13
AT504231A1 (de) 2008-04-15
EP2089708A1 (en) 2009-08-19
CA2669994A1 (en) 2008-04-10
WO2008040044A1 (en) 2008-04-10
US20100086570A1 (en) 2010-04-08
TW200826902A (en) 2008-07-01
US8062625B2 (en) 2011-11-22
AU2007304868A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
HK1215249A1 (zh) 標記的前列腺特異性膜抗原 的抑制子、生物學評估及作為成像試劑的用途
ZA201000095B (en) Multiple analysis of blood samples
DE602005027302D1 (de) Fluoreszenz endoskopisches Gerät
WO2008125747A3 (fr) Emulsions fluorescentes pour l'imagerie optique
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
DE502005011206D1 (de) Medizinisches Instrument für die Elektrochirurgie
DE602005022227D1 (de) Ultraschallbeobachtungsgerät
AP2010005249A0 (en) New antibodies specific of the B-amyloid peptides and their uses as diagnostic agents or drugs
FI20031753A (fi) Parannettu mittausjärjestely röntgenfluoresenssianalyysiä varten
BRPI0714642A2 (pt) "sequências do primer diagnóstico de tsv isolado, par de duas sequências do primer diagnóstico de tsv difenrentes, kit para detecção do tsv, métodos para a detecção da presença do tsv em uma amostra e método para q quantificação da quantidade de tsv em uma amostra"
CL2012002347A1 (es) Metodo in vitro para el diagnostico de la demencia con cuerpos de lewy (lbd), que comprende determinar en una muestra biológica de un individuo el genotipo de las siguientes alteraciones en el gen de la butirilcolinesterasa o de polimorfismos en desequilibrio de union de los mismos; kit para llevar a cabo dicho método; uso del kit para el diagnóstico de lbd.
DK2005182T3 (da) Kliniske korrelater
DK2118128T3 (da) Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1
EE200600030A (et) Proteiinkinaasi fluorestsents-sond
CL2007002853A1 (es) Procedimiento para predecir la eficacia de la inmunoterapia para cancer en un individuo, con respecto al beneficio clinico, que comprende proveer una muestra de sangre de dicho individuo, determinar el numero de linfocitos y neutrofilos en la sangre,
DE502006007255D1 (de) Medizinisches Instrument
DE602008004637D1 (de) Sicherungsmechanismus, insbesondere für Bluttrennungszentrifugen und dergleichen
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
BRPI0719390A2 (pt) Dispositivo de led para hemostasia de vasos sanguíneos
DE602007006249D1 (de) Vorrichtung zur Analyse fluoreszenter Röntgenstrahlen
BRPI0811873A2 (pt) Composição farmacêutica sólida efervescente que contém dextrose e procedimento para sua preparação.
IT1391101B1 (it) Apparecchiatura per foderare libri e simili
CL2007003395A1 (es) Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.
AR064206A1 (es) Parametros predictivos
ITMI20062153A1 (it) Fodera oerfezionata per libri quaderni e simili